Acute myocardial infarction

There are 490 papers on acute myocardial infarction in aging research: 19 trials and 396 observational studies in people, 13 in animals, 1 in cells, 41 reviews.

Disease

490 papers study it374 more mention it156 findings

148 new papers in 30 daysSee all 864 papers on acute myocardial infarction

“Statistically significant risk reduction was evident within 2–3 years [AMI: HR = 0.475, 95% confidence interval (CI) = 0.403–0.559;”
Smoking cessation duration and risk of acute myocardial infarction: A nationwide cohort study in KoreaAddiction (Abingdon, England)2026doi:10.1111/add.70710
  • Human trial19
  • Humans396
  • Animals13
  • Cells1
  • In silico9

Interventions

11

GLP-1 receptor agonists

no changein humans3downin humans1HR 1.033

4 studies
  1. GLP-1 receptor agonists were not clearly linked with acute myocardial infarction in humans.

    “acute myocardial infarction and incident heart failure with preserved ejection fraction did not differ significantly between cohorts”

    Humansin adults with obesity and CRP 3-10 mg/L; active comparator metformin, orlistat or phentermineup to 3,650 daysn = 50,009

    One drug class linked to fewer events in obesity with inflammation

    The American journal of cardiology

  2. GLP-1 receptor agonists were not clearly linked with acute myocardial infarction in humans (propensity-score matched cohort; 1-, 3- and 5-year follow-up).

    “No significant differences were noted in AMI or CVA at 1-, 3-, and 5-years of follow-up.”

    Humanspropensity-score matched cohort; 1-, 3- and 5-year follow-up1, 3 and 5 years

    Long-Term Impact of GLP-1 Receptor Agonists on Cardiovascular Outcomes in Patients Treated with Hematopoietic Stem Cell Transplantation: A Propensity-Score Matched Analysis

    AHA Scientific Sessions 2025 abstract

  3. GLP-1 receptor agonists were not clearly linked with acute myocardial infarction in humans (propensity-matched cohort; GLP-1RA started within 14 days after TAVI) (HR 1.033).

    “No differences were observed in AMI (HR 1.033 [95% CI, 0.750-1.423]; p=0.844)”

    Humanspropensity-matched cohort; GLP-1RA started within 14 days after TAVI1 yearn = 930

    GLP-1 Receptor Agonists and Cardiovascular Outcomes in Patients with Type 2 Diabetes Undergoing TAVI: A Real-World Cohort Study

    AHA Scientific Sessions 2025 abstract

  4. GLP-1 receptor agonists are linked with lower acute myocardial infarction in humans (patients with T2DM and ESRD compared with matched non-users) (1.74% vs. 3.83%, OR 0.445, CI 0.297-0.667).

    “as well as AMI (1.74% vs. 3.83%, OR 0.445, CI 0.297-0.667, p < 0.0001).”

    Humanspatients with T2DM and ESRD compared with matched non-usersat least 6 months of therapyn = 2,009

    MON-521 GLP-1 Receptor Agonists and Risk for Dialysis, Cardiovascular Disease and Mortality in Patients with Type 2 Diabetes Mellitus and End Stage Renal Disease

    ENDO 2025 abstract

More on GLP-1 receptor agonists

SGLT2 inhibitors

no changein humans2RR 0.85–1.044

2 studies
  1. SGLT2 inhibitors were not clearly linked with acute myocardial infarction in humans (heart failure patients after TAVR, propensity score-matched cohort) (14.4% vs. 13.8%; RR 1.044 (95% CI 0.800-1.363)).

    “Acute MI (14.4% vs. 13.8%; RR=1.044, 95% CI: 0.800-1.363, p=0.752)”

    Humansheart failure patients after TAVR, propensity score-matched cohortn = 660

    SGLT2 inhibitors improve clinical outcomes in patients with heart failure undergoing transcatheter aortic valve replacement: real world evidence from the trinetx database

    ESC Congress 2026 abstract

  2. SGLT2 inhibitors were not clearly linked with acute myocardial infarction in patients receiving immune checkpoint inhibitors, after propensity score matching (RR 0.85, 95% CI 0.592-1.212).

    “The risk of AMI (RR 0.85, 95% CI: 0.592-1.212, p-value 0.3625) and myocarditis (RR 1.001, 95% CI: 0.417-2.401, p-value 0.998) was similar between both groups.”

    Humansin patients receiving immune checkpoint inhibitors, after propensity score matchingn = 2,862

    Effect Of SGLT2 Inhibitors On Cardiovascular Protection In Patients Undergoing Immune Checkpoint Therapy

    AHA Scientific Sessions 2025 abstract

More on SGLT2 inhibitors

Inclisiran

no changein humans1HR 1.33

1 study
  1. Inclisiran was not clearly linked with acute myocardial infarction in humans (8.2% vs 7.6%; HR 1.33, 95% CI 0.76–2.33; p=0.32).

    “Inclisiran use was not significantly associated with acute myocardial infarction (8.2% vs 7.6%; HR, 1.33; 95% CI, 0.76 - 2.33; p=0.32)”

    HumansMASLD and elevated cardiovascular risk; receiving statin and ezetimibe therapy; compared with no inclisiran3 yearsn = 317

    Cardiovascular Outcomes of Inclisiran in Patients with Elevated Cardiovascular Risk and Metabolic Dysfunction Associated Steatotic Liver Disease

    AHA Scientific Sessions 2026 abstract

More on Inclisiran

Semaglutide

no changein humans1RR 1.15

1 study
  1. Semaglutide was not clearly linked with acute myocardial infarction in humans (3.6% vs. 3.1%; RR 1.15, 95% CI 0.69-1.93).

    “No significant differences were observed in stroke or acute MI.”

    HumansAtrial fibrillation with obesity or diabetes following catheter ablation; compared with tirzepatide3 years65% males

    Comparative cardiovascular outcomes of semaglutide versus tirzepatide in patients with atrial fibrillation undergoing catheter ablation: a retrospective cohort study

    ESC Congress 2026 abstract

More on Semaglutide

Tirzepatide

no changein humans1

1 study
  1. Tirzepatide was not clearly linked with acute myocardial infarction in humans (healthcare professional reports only) (ROR 0.45 [0.19-1.08]).

    “no disproportionate reporting was detected for acute myocardial infarction (ROR 0.45 [0.19-1.08])”

    Humanshealthcare professional reports only

    Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events

    Frontiers in pharmacology

More on Tirzepatide

Occupational noise

no changein humans1OR 1.008

1 study
  1. Occupational noise was not clearly linked with acute myocardial infarction in humans (OR 1.008, 95% CI 0.998-1.018).

    “acute myocardial infarction (P = .112; OR: 1.008; 95% CI: 0.998-1.018)”

    Humans

    Exploring the effects of occupational noise on cardiovascular and cerebrovascular diseases: A Mendelian randomization study

    Medicine

More on Occupational noise

Poverty

no changein humans1HR 1.1

1 study
  1. Poverty was not clearly linked with acute myocardial infarction in humans (cardiovascular risk factors) (HR 1.10, 95% CI 0.93 to 1.31).

    “the association remained significant among women (HR 1.30, 95% CI 1.01 to 1.68), but not among men (HR 1.10, 95% CI 0.93 to 1.31).”

    Humanscardiovascular risk factorsmalesn = 53,564

    Municipal multidimensional poverty increases the risk of acute myocardial infarction: a retrospective cohort study with sex-stratified analyses in Chile's public health system

    BMJ open

More on Poverty

Physical activity

no changein humans1HR 0.95

1 study
  1. Physical activity was not clearly linked with acute myocardial infarction in humans (HR 0.95, 95% CI 0.72-1.25).

    “There was no association between high-volume PA (>3000 MET-minutes per week) and risk for acute myocardial infarction (HR, 0.95 [95% CI, 0.72-1.25]).”

    Humans>3000 MET-minutes per week20.5 yearsn = 26,724

    High-Volume Physical Activity and Clinical Coronary Artery Disease Outcomes: Findings From the Cooper Center Longitudinal Study

    Circulation

More on Physical activity

Ambient temperature

no changein humans1RR 0.999

1 study
  1. Ambient temperature was not clearly linked with acute myocardial infarction in humans (when it is 26°C) (RR 0.999 (95% CI 0.986, 1.012)).

    “become increasing again when it is 26°C although not significantly (Risk ratio = 0.999 (95% CI 0.986, 1.012)”

    Humanswhen it is 26°C

    Importance of applying Mixed Generalized Additive Model (MGAM) as a method for assessing the environmental health impacts: Ambient temperature and Acute Myocardial Infarction (AMI), among elderly in Shanghai, China

    PloS one

More on Ambient temperature

Dutasteride

no changein humans1HR 0.94

1 study
  1. Dutasteride was not clearly linked with acute myocardial infarction in humans (relative to finasteride) (HR 0.94, 95% CI 0.82-1.08).

    “Similarly, we found no difference in the risk of acute myocardial infarction (HR 0.94, 95% CI 0.82-1.08) or stroke (HR 1.03, 95% CI 0.88-1.20).”

    Humansrelative to finasteridemales

    The Cardiovascular Safety of Dutasteride

    The Journal of urology

More on Dutasteride

All 11

Effects

2

Inflammation

upin humans1

1 study
  1. Acute myocardial infarction is linked with higher inflammation in humans (compared with older healthy controls).

    “a significantly greater proportion of intermediate and non-classical CD80+ monocytes suggested a shift to a pro-inflammatory phenotype”

    Humanscompared with older healthy controlsblood monocytesn = 21

    Age-related M1/M2 phenotype changes in circulating monocytes from healthy/unhealthy individuals

    Aging

More on Inflammation

Classical CD163+CD80+ monocytes

downin humans1

1 study
  1. Acute myocardial infarction is linked with lower classical CD163+CD80+ monocytes in humans (compared with older healthy controls).

    “The AMI patients showed a significantly decreased proportion of CD163+CD80+ and an increased proportion of CD163+ and CD163−CD80− cells among classical monocytes, opposite trends to those observed in healthy aging”

    Humanscompared with older healthy controlsblood monocytesn = 21

    Age-related M1/M2 phenotype changes in circulating monocytes from healthy/unhealthy individuals

    Aging

Upstream

5

FI-LAB

no changein humans1HR 0.995

1 study
  1. FI-LAB was not clearly linked with acute myocardial infarction in humans (patients with acute coronary syndrome undergoing percutaneous coronary intervention) (HR 0.995; 95% CI 0.854-1.160).

    “but not with recurrent AMI (HR 0.995; 95% CI 0.854-1.160).”

    Humanspatients with acute coronary syndrome undergoing percutaneous coronary intervention

    Frailty Status and Outcomes in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a multicentre retrospective cohort study

    European journal of cardiovascular nursing

More on FI-LAB

Cholesterol uptake capacity

no changein humans1

1 study
  1. Cholesterol uptake capacity was not clearly linked with acute myocardial infarction in humans (1.11 ± 0.45 vs. 1.16 ± 0.55, p = 0.6).

    “non-significantly lower in the non-AMI vs. AMI group (1.11 ± 0.45 vs. 1.16 ± 0.55; p = 0.6)”

    Humansserum

    Serum high-density lipoprotein cholesterol uptake capacity and cardiovascular risk in subjects from the Birjand longitudinal aging study

    Journal of diabetes and metabolic disorders

More on Cholesterol uptake capacity

HbA1c variability

no changein humans1HR 0.88

1 study
  1. HbA1c variability was not clearly linked with acute myocardial infarction in humans (type 2 diabetes) (HR = 0.88, 95% CI: 0.51-1.52).

    “No significant associations were observed between HbA1c variability and AMI (HR = 0.88, 95% CI: 0.51-1.52)”

    Humanstype 2 diabetesn = 18,293

    Visit-to-visit HbA1c variability, risk of all-cause mortality and diabetes-related vascular complications among adult individuals with type 2 diabetes mellitus

    Diabetes, obesity & metabolism

More on HbA1c variability

Inflammation

mediatesin humans1

1 study
  1. Inflammation is linked with acute myocardial infarction in humans (mediating CVH-AMI relationship) (1.57-8.62 %).

    “Inflammatory/metabolic biomarkers mediated 1.57-8.62 % of the CVH-AMI relationship.”

    Humansmediating CVH-AMI relationshipn = 122,914

    Life's essential 8 scores and acute myocardial infarction: Associations with risk, onset delay, and scenario-based preventable fraction estimates

    American journal of preventive cardiology

More on Inflammation

Female sex

no changein humans1HR 1.02

1 study
  1. female sex was not clearly linked with acute myocardial infarction in propensity-matched heart failure patients with cardiac amyloidosis on SGLT2 inhibitors (HR 1.02; 95% CI, 0.73–1.44).

    “acute myocardial infarction (HR 1.02; 95% CI, 0.73–1.44)”

    Humansin propensity-matched heart failure patients with cardiac amyloidosis on SGLT2 inhibitors3 yearsn = 466

    Sex-related differences in clinical outcomes among heart failure patients with cardiac amyloidosis on SGLT2i therapy

    AHA Scientific Sessions 2025 abstract

Associations

115

SGLT2 inhibitors

downin humans6upin humans1HR 0.53–0.76

7 studies
  1. SGLT2 inhibitors are associated with acute myocardial infarction in humans (OR 0.64, 95% CI 0.53–0.77).

    “and acute myocardial infarction (OR 0.64; 95% CI 0.53-0.77).”

    HumansPatients with diabetes and bioprosthetic heart valves; propensity-score-matched comparison with non-usersApproximately 2.8±1.8 years

    SGLT2 Inhibitor Use and Bioprosthetic Valve Re-Intervention in Patients with Diabetes

    AHA Scientific Sessions 2026 abstract

  2. SGLT2 inhibitors are associated with acute myocardial infarction in humans (RR 0.685, 95% CI 0.534–0.878; Kaplan-Meier analysis not statistically significant).

    “Risk analysis showed lower rates of STEMI/acute MI (RR 0.685, 95% CI 0.534-0.878)”

    HumansDialysis-dependent end-stage renal disease and HFrEF; risk analysis, with nonsignificant Kaplan-Meier analysisn = 998

    SGLT2 Inhibitor Use in ESRD and HFrEF: A Retrospective Outcomes Analysis

    AHA Scientific Sessions 2026 abstract

  3. SGLT2 inhibitors are associated with acute myocardial infarction in humans (HR 0.76, 95% CI 0.57-0.99).

    “AMI was significantly less at 5 years (HR 0.76; 95% CI 0.57-0.99; p=0.045)”

    Humanscancer therapy-related HFrEF; SGLT2 inhibitor-based GDMT versus GDMT without SGLT2 inhibitors5 years

    SGLT2 Inhibitors and Major Adverse Cardiovascular Events in Chemotherapy-Related Cardiomyopathy: A Real-World Comparative Effectiveness Study

    AHA Scientific Sessions 2026 abstract

  4. SGLT2 inhibitors are associated with acute myocardial infarction in humans (moderate-to-severe plaque psoriasis receiving biologic therapy) (HR 0.601; 95% CI 0.426–0.849).

    “SGLT2 inhibitor use was associated with a significantly lower incidence of acute myocardial infarction (HR, 0.601; 95%CI, 0.426-0.849)”

    Humansmoderate-to-severe plaque psoriasis receiving biologic therapy

    SGLT2 inhibitors and cardiovascular outcomes in patients with moderate-to-severe psoriasis receiving biologic therapy: A propensity score-matched cohort study

    Actas dermo-sifiliograficas

  5. SGLT2 inhibitors are linked with a lower risk of acute myocardial infarction in adults with Fabry disease, propensity-matched TriNetX cohort (HR 0.53; 95% CI 0.30-0.90).

    “with reduced myocardial infarction risk (HR 0.53; 95% CI 0.30-0.90)”

    Humansin adults with Fabry disease, propensity-matched TriNetX cohort5 yearsn = 732

    SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network

    Diabetes, obesity & metabolism

  6. SGLT2 inhibitors are linked with a higher risk of acute myocardial infarction in humans (propensity-matched adults aged 80 years or older with chronic kidney disease).

    “Acute myocardial infarction and acute heart failure were increased in the SGLT2i group.”

    Humanspropensity-matched adults aged 80 years or older with chronic kidney diseasetwo yearsn = 10,076

    Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in the Very Elderly with Chronic Kidney Disease: a Retrospective Cohort Study Using Real-World Data

    medRxivPreprint

  7. SGLT2 inhibitors are associated with acute myocardial infarction in humans (HR 0.64; 95% CI 0.56-0.72).

    “SGLT2 inhibitor use was associated with fewer heart failure hospitalizations (HR 0.78; 95% CI 0.72-0.85) and acute myocardial infarctions (HR 0.64; 95% CI 0.56-0.72).”

    Reviewstage 5 chronic kidney disease; association was no longer significant in treatment-initiation cohortsn = 57,156

    SGLT2 Inhibitors in Stage 5 Chronic Kidney Disease: A Systematic Review and Meta-analysis of Cardiovascular and Kidney Outcomes

    medRxivPreprint

More on SGLT2 inhibitors

GLP-1 receptor agonists

downin humans4HR 0.63–1.234

4 studies
  1. GLP-1 receptor agonists are linked with a lower risk of acute myocardial infarction in humans (Type 2 diabetes and cancer; compared with DPP-4 inhibitors) (142 vs 212 events; HR 0.72, 95% CI 0.58–0.89).

    “GLP-1 RA was associated with lower risk of MI (142 vs 212 events; HR 0.72, 95% CI 0.58-0.89)”

    HumansType 2 diabetes and cancer; compared with DPP-4 inhibitors2 years51% males

    GLP-1 Receptor Agonists and Arterial and Venous Thromboembolism in Patients with Type 2 Diabetes and Cancer: A Propensity-Matched Cohort Study

    AHA Scientific Sessions 2026 abstract

  2. GLP-1 receptor agonists are linked with a lower risk of acute myocardial infarction in humans (HR 1.234, 95% CI 1.192–1.276 (SGLT2i versus GLP-1RA)).

    “GLP-1RA therapy was associated with lower risk of acute myocardial infarction (HR 1.234, 95% CI 1.192–1.276; p<0.001)”

    HumansObesity and type 2 diabetes mellitus; compared with SGLT2 inhibitors; reported HR uses SGLT2i versus GLP-1RA30 days through 5 years

    Beyond Glycemic Control: Primary Prevention of Heart Failure with Preserved Ejection Fraction with Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists

    AHA Scientific Sessions 2026 abstract

  3. GLP-1 receptor agonists are associated with acute myocardial infarction in humans (Morbid obesity; users compared with propensity score-matched non-users) (HR 0.69, 95% CI 0.63–0.77).

    “Overall, GLP-1 RA therapy was associated with lower risks of SCD, VT/VF, AMI, and all-cause mortality”

    HumansMorbid obesity; users compared with propensity score-matched non-users5 years

    Obesity drugs linked to lower sudden cardiac death risk

    AHA Scientific Sessions 2026 abstract

  4. GLP-1 receptor agonists are linked with a lower risk of acute myocardial infarction in humans (HR 0.63 (95% CI 0.54–0.73)).

    “AMI (HR 0.63, 95% CI 0.54–0.73, p < 0.001)”

    Humansin adults with HFpEF, type 2 diabetes and obesity, compared with standard of care without GLP-1 RAs3 yearsn = 5,474

    Glucagon-Like Peptide-1 Receptor Agonists with Guideline Therapy Lower Mortality and Hospitalizations in HFpEF: A Propensity-Matched U.S. TriNetX Study

    AHA Scientific Sessions 2025 abstract

More on GLP-1 receptor agonists

Tirzepatide

downin humans3HR 0.21–0.71

3 studies
  1. Tirzepatide is associated with acute myocardial infarction in humans (PCOS and T2DM receiving metformin; propensity-matched comparison with no tirzepatide) (1.2% vs 7.5%; HR 0.21, 95% CI 0.03–0.35).

    “acute myocardial infarction (1.2% vs 7.5%; HR, 0.21; 95% CI, 0.03 - 0.35; p<0.01)”

    HumansPCOS and T2DM receiving metformin; propensity-matched comparison with no tirzepatide5 yearsfemalesn = 4,345

    Five-Year Cardiovascular Outcomes of Tirzepatide in Women with Polycystic Ovarian Syndrome and Type 2 Diabetes Mellitus Receiving Metformin

    AHA Scientific Sessions 2026 abstract

  2. Tirzepatide is associated with acute myocardial infarction in humans (elevated lipoprotein(a)) (HR 0.71; 95% CI, 0.52-0.98).

    “tirzepatide use was associated with a lower hazard of MACE (HR 0.72; 95% CI, 0.58-0.89), AMI (HR 0.71; 95% CI, 0.52-0.98)”

    Humanselevated lipoprotein(a)2 years

    Tirzepatide Use and Major Adverse Cardiovascular Events Among Patients with Elevated Lipoprotein(a)

    AHA Scientific Sessions 2026 abstract

  3. Tirzepatide is linked with a lower risk of acute myocardial infarction in humans (propensity-matched comparison with GLP-1RAs in adults with T2DM and ischemic heart disease) (HR 0.59, 95% CI 0.38-0.91).

    “acute myocardial infarction (HR: 0.59, 95% CI: 0.38-0.91)”

    Humanspropensity-matched comparison with GLP-1RAs in adults with T2DM and ischemic heart disease1-year follow-up

    An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists

    JACC. Advances

More on Tirzepatide

In-hospital mortality

upin humans3OR 2.79

3 studies
  1. Acute myocardial infarction is associated with in-hospital mortality in humans (hospitalized with RSV-associated ARIs) (mOR 3.05, p = 0.005).

    “and acute myocardial infarction (3.05, p = 0.005)”

    Humanshospitalized with RSV-associated ARIs

    Respiratory Syncytial Virus Hospitalizations Among Adults in Thailand: A Nationwide Retrospective Observational Study (RSV-HAT)

    Influenza and other respiratory viruses

  2. Acute myocardial infarction is associated with in-hospital mortality in humans (OR 2.79; 95% CI 1.86–4.20).

    “the strongest risk factors for in-hospital death for patients with a RRS call were advanced malignancy (OR 3.95; 95%CI 2.16-7.21) and new myocardial infarction (OR 2.79; 95%CI 1.86-4.20).”

    HumansPatients receiving Rapid Response System attendances; adjusted for all investigated clinical indicatorsn = 328

    Pre-existing risk factors for in-hospital death among older patients could be used to initiate end-of-life discussions rather than Rapid Response System calls: A case-control study

    Resuscitation

  3. Acute myocardial infarction predicts in-hospital mortality in humans (Acute myocardial infarction less than 7 days before coronary artery bypass grafting).

    “On multivariate logistic regression non sinus rhythm and acute myocardial infarction less than 7 days before surgery were independent predictors of in-hospital mortality.”

    HumansAcute myocardial infarction less than 7 days before coronary artery bypass graftingIn-hospitaln = 182

    Elective and urgent coronary surgery in octogenarians

    Revista portuguesa de cirurgia cardio-toracica e vascular : orgao oficial da Sociedade Portuguesa de Cirurgia Cardio-Toracica e Vascular

Fine particulate matter

upin humans3

3 studies
  1. Fine particulate matter is associated with acute myocardial infarction in humans.

    “Each 10-μg/m3 increase in lag-2 PM2.5 was significantly associated with an increased risk of AMI.”

    HumansEach 10-μg/m3 increase in PM2.5 exposure2-day lagn = 270,091

    Air pollution before and during the COVID-19 pandemic: changes in risk of acute myocardial infarction

    European heart journal

  2. Fine particulate matter is linked with a higher risk of acute myocardial infarction in humans (cumulative exposure Q4 vs Q1, fully adjusted) (IRR 1.24 [95% CI 1.18,1.31]).

    “The most pronounced association was observed for PM2.5 with IRRs of 1.08 [95% CI 1.04,1.13], 1.14 [95% CI 1.09,1.20] and 1.24 [95% CI 1.18,1.31] in Q2–Q4”

    Humanscumulative exposure Q4 vs Q1, fully adjustedn = 903,415

    Long-term exposure to ambient air pollution and risk of incident acute myocardial infarction in a nationwide register-based cohort study

    International archives of occupational and environmental health

  3. Fine particulate matter is linked with a higher risk of acute myocardial infarction in humans (adjusted for individual risk factors).

    “the Hazard Ratio (HR) for AMI and Ischemic Heart Disease (IHD) was 1.031 [0.95 CI = 1.005, 1.057]”

    Humansadjusted for individual risk factors10 μg/m3 increase15 yearsn = 3,081

    Long-term exposure to PM2.5 and cardiovascular disease incidence and mortality in an Eastern Mediterranean country: findings based on a 15-year cohort study

    Environmental health : a global access science source

More on Fine particulate matter

Smoking

upin humans2OR 3.51

2 studies
  1. Smoking is associated with acute myocardial infarction in humans (Prediagnostic smoking trajectories) (OR 3.51).

    “The strongest associations were observed for acute myocardial infarction (OR 3.51) and cerebral infarction (OR 2.46).”

    HumansPrediagnostic smoking trajectories

    Prediagnostic smoking intensity trajectories and subtype-specific vascular disease risk in a nationwide health screening population

    International journal of public health

  2. Smoking raises the risk of acute myocardial infarction in humans.

    “smoking remains the most consistent risk factor”

    Review

    Acute myocardial infarction in young adults: Changes in risk profile over the last decades

    International Health Sciences Review

More on Smoking

Statins

downin humans1upin humans1HR 0.805–5.34

2 studies
  1. Statins are linked with a lower risk of acute myocardial infarction in humans (without prior cardiovascular disease) (HR 0.805, 95% CI 0.731-0.887).

    “In the fully adjusted Cox model, baseline statin exposure was associated with a lower risk of incident AMI (HR, 0.805; 95% CI, 0.731-0.887).”

    Humanswithout prior cardiovascular diseasemedian follow-up of 5 yearsn = 174,014

    Baseline Statin Exposure and Incident Acute Myocardial Infarction in Adults Aged >=75 Years Without Prior Cardiovascular Disease: A Population-Based Cohort Study

    medRxivPreprint

  2. Statins are linked with a higher risk of acute myocardial infarction in humans (incident ESRD requiring permanent dialysis) (1.51% vs. 0.30%, HR 5.34 (95% CI 3.40-8.39)).

    “acute myocardial infarction (1.51% vs. 0.30%, HR: 5.34, 95% CI: 3.40-8.39) compared to the nonstatin group (n = 1709).”

    Humansincident ESRD requiring permanent dialysis> 90 days in the first year after initiation of dialysis

    Does Statin Therapy Reduce the Risks of Mortality and Major Adverse Cardiac and Cerebrovascular Events in Young Adults with End-Stage Renal Disease? Population-Based Cohort Study

    Journal of clinical medicine

More on Statins

Air pollution

upin humans2

2 studies
  1. Air pollution is linked with a higher risk of acute myocardial infarction in humans.

    “Our main analyses showed a clear exposure-response relationship between cumulative exposure to each of the air pollutants and incident AMI.”

    Humansn = 903,415

    Long-term exposure to ambient air pollution and risk of incident acute myocardial infarction in a nationwide register-based cohort study

    International archives of occupational and environmental health

  2. Air pollution raises the risk of acute myocardial infarction in humans.

    “new emerging risk factors like air pollution (micro- and nanoplastics), periodontitis, acute stress, energy drinks, misuse of recreational drugs may increase risk and influence treatment, and outcomes of AMI in this young population.”

    Review

    Young hearts at risk: Unveiling novel factors in myocardial infarction susceptibility and prevention

    Journal of family medicine and primary care

More on Air pollution

Mortality

upin humans2HR 4.631

2 studies
  1. Acute myocardial infarction is linked with a higher risk of mortality in humans (elderly patients with intertrochanteric fractures) (HR 4.631, 95% CI 2.190-9.795).

    “AMI (HR 4.631, 95% CI 2.190-9.795, P < 0.001)”

    Humanselderly patients with intertrochanteric fractures

    All-Cause Mortality Risk in Elderly Patients with Femoral Neck and Intertrochanteric Fractures: A Predictive Model Based on Machine Learning

    Clinical interventions in aging

  2. Acute myocardial infarction is linked with a higher risk of mortality in humans after femoral neck fracture surgery (OR 1.317, 95% CI 1.240-1.400).

    “acute myocardial infarction (AMI) (OR 1.317; 95% CI, 1.240-1.400)”

    Humansafter femoral neck fracture surgery1 year

    Epidemiology, treatment, and mortality of femoral neck fractures in patients over the age of 65 years: a nationwide retrospective cohort study of 83,789 cases in Turkey

    Hip international : the journal of clinical and experimental research on hip pathology and therapy

Low serum magnesium

upin humans1HR 1.77

1 study
  1. Low serum magnesium is associated with acute myocardial infarction in humans (Prior metabolic and bariatric surgery; low versus normal magnesium) (HR 1.77, 95% CI 1.24–2.53).

    “Low magnesium was associated with higher mortality (HR 1.34, 95% CI 1.06–1.69) and higher hazards of acute myocardial infarction (HR 1.77, 95% CI 1.24–2.53)”

    HumansPrior metabolic and bariatric surgery; low versus normal magnesiumDay 90 through 3 years

    Low Serum Magnesium and Long-Term Mortality in Adults With Prior Metabolic and Bariatric Surgery: A Multicenter Propensity Score–Matched Cohort Study

    Frontiers in nutrition

More on Low serum magnesium

All 115

Trial sponsors

Funding

9 grants since 2016

National Heart, Lung, and Blood Institute$4.8MAmerican Heart Association$307KJapan Society for the Promotion of Science¥3.4M

Latest

Dec 2025: 18Jan 2026: 33Feb 2026: 37Mar 2026: 25Apr 2026: 10May 2026: 14Jun 2026: 12Jul 2026: 12Aug 2026: 31Sep 2026: 12Oct 2026: 90Nov 2026: 70364 papers in 12 months

See all 864 papers on acute myocardial infarction